VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q73066245 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235948.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q73066245‏
024 ‎‡a 0000-0002-3414-2707‏ ‎‡2 orcid‏
024 ‎‡a 7004101549‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q73066245‏
100 0 ‎‡a Pedro J Serrano-Castro‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Serrano-Castro PJ‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's [A historical description of the association of macro-orchidea, mental retardation and cranial dysmorphia in males (fragile X chromosome syndrome) by A.B. Richerand].‏
670 ‎‡a Author's A transcranial doppler study in interictal migraine and tension-type headache.‏
670 ‎‡a Author's Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study.‏
670 ‎‡a Author's [Advances in our knowledge of the causation and pathophysiology of reflex epilepsies]‏
670 ‎‡a Author's Agraphia manifesting during a WhatsApp conversation‏
670 ‎‡a Author's Analysis of factors influencing telephone call response rate in an epidemiological study.‏
670 ‎‡a Author's Antiepileptic treatment in patients with epilepsy and other comorbidities.‏
670 ‎‡a Author's Cerebral hemodynamics in the syndrome of pseudomigraine with csf-pleocytosis:a transcranial doppler study‏
670 ‎‡a Author's Characteristics of temporal lobe epilepsy with no ictal impairment of consciousness.‏
670 ‎‡a Author's Cognitive Profile of Zonisamide and Valproic Acid in the Treatment of Idiopathic Generalized Epilepsy: A Comparative Observational Study.‏
670 ‎‡a Author's Consensus clinical practice guidelines of the Andalusian Epilepsy Society: therapeutic recommendations when dealing with a first epileptic seizure and in epileptic status‏
670 ‎‡a Author's Consensus clinical practice guidelines of the Sociedad Andaluza de Epilepsia for the diagnosis and treatment of patients with their first epileptic seizure in emergencies‏
670 ‎‡a Author's Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide.‏
670 ‎‡a Author's Controversies about the new anti-epileptic drugs‏
670 ‎‡a Author's Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway‏
670 ‎‡a Author's [Descriptive analysis of the e-mail list "Neurología-RedIRIS" (http://listserv.rediris.es/neurologia.html): an active, plural instrument having scientific quality at the reach of the Spanish speaking neurology sector]‏
670 ‎‡a Author's Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)‏
670 ‎‡a Author's Early add-on lacosamide in a real-life setting: results of the REALLY study‏
670 ‎‡a Author's Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review‏
670 ‎‡a Author's EPICON consensus: recommendations for proper management of switching to eslicarbazepine acetate in epilepsy.‏
670 ‎‡a Author's [Epidemiological features of epilepsy in adults requiring hospital admission]‏
670 ‎‡a Author's [Epidemiology of epilepsy in Spain and Latin America]‏
670 ‎‡a Author's Eslicarbazepine acetate and carotid intima-media thickness in epileptic patients.‏
670 ‎‡a Author's Eslicarbazepine acetate in clinical practice. Efficacy and safety results‏
670 ‎‡a Author's Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment‏
670 ‎‡a Author's [Hemifacial spasm as manifestation of benign intracranial hypertension. Letter]‏
670 ‎‡a Author's Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic?‏
670 ‎‡a Author's Incidence and case fatality rate of COVID-19 in patients with active epilepsy‏
670 ‎‡a Author's Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study‏
670 ‎‡a Author's Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab‏
670 ‎‡a Author's [Malignant middle cerebral artery infarction: medical or surgical treatment?]‏
670 ‎‡a Author's Menstrual tension-type headache: evidence for its existence.‏
670 ‎‡a Author's Mesial temporal sclerosis (I): histological data, physiopathological hypothesis and etiological factors‏
670 ‎‡a Author's [Migraine with episodic unilateral mydriasis: parasympathetic dysfunction or adrenergic hyperactivity?]‏
670 ‎‡a Author's Miller-Fisher syndrome after SARS-CoV-2 infection‏
670 ‎‡a Author's Multiple cerebral haemorrhages and antiplatelet drugs‏
670 ‎‡a Author's [Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases]‏
670 ‎‡a Author's Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations.‏
670 ‎‡a Author's [Partial epilepsy refractory to medical treatment and occipital porencephalic lesion]‏
670 ‎‡a Author's Possible case of peripheral osmotic demyelination syndrome‏
670 ‎‡a Author's Preoperative evaluation by functional magnetic resonance imaging in patients with dysembryoplastic neuroepithelial tumours: A case series‏
670 ‎‡a Author's [Pseudomigraine with pleocytosis and the 'invisibility' of the original reports in Spanish.]‏
670 ‎‡a Author's [Refractory epilepsy in adults]‏
670 ‎‡a Author's Regarding: 'Mosaicism and seizure onset in ring chromosome 20 syndrome'‏
670 ‎‡a Author's Response to immunotherapy in anti-IgLON5 disease: A systematic review‏
670 ‎‡a Author's Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.‏
670 ‎‡a Author's Ring chromosome 20 epilepsy syndrome in children: electroclinical features‏
670 ‎‡a Author's Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature‏
670 ‎‡a Author's Stiff person syndrome (SPS), a basal ganglia disease? Striatal MRI lesions in a patient with SPS.‏
670 ‎‡a Author's [Sudden aphasia in a young woman]‏
670 ‎‡a Author's [Surgery for temporal-lobe epilepsy: is eradicating seizures enough?]‏
670 ‎‡a Author's The Andalusia Epilepsy Society's Guide to Epilepsy Therapy 2005: I. Criteria for starting and discontinuing and the pharmacological bases of antiepileptic treatment‏
670 ‎‡a Author's [The Andalusia Epilepsy Society's Guide to Epilepsy Therapy 2005: II. Chronic therapy with antiepileptic drugs in adults and in children].‏
670 ‎‡a Author's [The Andalusia Epilepsy Society's Guide to Epilepsy Therapy 2005: IV. General principles of antiepileptic polytherapy and therapeutic strategies in refractory epilepsy].‏
670 ‎‡a Author's The expanding spectrum of febrile infection-related epilepsy syndrome‏
670 ‎‡a Author's The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES).‏
670 ‎‡a Author's The red ear syndrome: five new cases.‏
670 ‎‡a Author's [Transcranial Doppler ultrasonography in the diagnosis of a pulmonary arteriovenous fistula]‏
670 ‎‡a Author's [Transient topographical amnesia: a description of a series of eight cases].‏
670 ‎‡a Author's Treatment adherence with levetiracetam: a non-interventionist retrospective observation-based study‏
670 ‎‡a Author's [Trigeminal-autonomic cephalalgias: International Headache Society diagnostic criteria does not allow for a correct classification]‏
670 ‎‡a Author's Validation of a short useful questionnaire in Spanish for the epidemiological screening of epilepsy in Spain. EPIBERIA Questionnaire.‏
670 ‎‡a Author's [Vasomotor reactivity throught the voluntary apnea test can be measured without calculating the apnea index]‏
670 ‎‡a Author's Will neurological care change over the next 5 years due to the COVID-19 pandemic?‏
909 ‎‡a (scopus) 7004101549‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000234142707‏ ‎‡9 1‏
919 ‎‡a willneurologicalcarechangeoverthenext5yearsduetothecovid19pandemic‏ ‎‡A Will neurological care change over the next 5 years due to the COVID-19 pandemic?‏ ‎‡9 1‏
919 ‎‡a vasomotorreactivitythroughtthevoluntaryapneatestcanbemeasuredwithoutcalculatingtheapneaindex‏ ‎‡A [Vasomotor reactivity throught the voluntary apnea test can be measured without calculating the apnea index]‏ ‎‡9 1‏
919 ‎‡a validationofashortusefulquestionnaireinspanishfortheepidemiologicalscreeningofepilepsyinspainepiberiaquestionnaire‏ ‎‡A Validation of a short useful questionnaire in Spanish for the epidemiological screening of epilepsy in Spain. EPIBERIA Questionnaire.‏ ‎‡9 1‏
919 ‎‡a trigeminalautonomiccephalalgiasinternationalheadachesocietydiagnosticcriteriadoesnotallowforacorrectclassification‏ ‎‡A [Trigeminal-autonomic cephalalgias: International Headache Society diagnostic criteria does not allow for a correct classification]‏ ‎‡9 1‏
919 ‎‡a treatmentadherencewithlevetiracetamanoninterventionistretrospectiveobservationbasedstudy‏ ‎‡A Treatment adherence with levetiracetam: a non-interventionist retrospective observation-based study‏ ‎‡9 1‏
919 ‎‡a transienttopographicalamnesiaadescriptionofaseriesof8cases‏ ‎‡A [Transient topographical amnesia: a description of a series of eight cases].‏ ‎‡9 1‏
919 ‎‡a transcranialdopplerultrasonographyinthediagnosisofapulmonaryarteriovenousfistula‏ ‎‡A [Transcranial Doppler ultrasonography in the diagnosis of a pulmonary arteriovenous fistula]‏ ‎‡9 1‏
919 ‎‡a redearsyndrome5newcases‏ ‎‡A The red ear syndrome: five new cases.‏ ‎‡9 1‏
919 ‎‡a expandingspectrumoffebrileinfectionrelatedepilepsysyndromefires‏ ‎‡A The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES).‏ ‎‡9 1‏
919 ‎‡a expandingspectrumoffebrileinfectionrelatedepilepsysyndrome‏ ‎‡A The expanding spectrum of febrile infection-related epilepsy syndrome‏ ‎‡9 1‏
919 ‎‡a andalusiaepilepsysocietysguidetoepilepsytherapy20054generalprinciplesofantiepilepticpolytherapyandtherapeuticstrategiesinrefractoryepilepsy‏ ‎‡A [The Andalusia Epilepsy Society's Guide to Epilepsy Therapy 2005: IV. General principles of antiepileptic polytherapy and therapeutic strategies in refractory epilepsy].‏ ‎‡9 1‏
919 ‎‡a andalusiaepilepsysocietysguidetoepilepsytherapy20052chronictherapywithantiepilepticdrugsinadultsandinchildren‏ ‎‡A [The Andalusia Epilepsy Society's Guide to Epilepsy Therapy 2005: II. Chronic therapy with antiepileptic drugs in adults and in children].‏ ‎‡9 1‏
919 ‎‡a andalusiaepilepsysocietysguidetoepilepsytherapy20051criteriaforstartinganddiscontinuingandthepharmacologicalbasesofantiepileptictreatment‏ ‎‡A The Andalusia Epilepsy Society's Guide to Epilepsy Therapy 2005: I. Criteria for starting and discontinuing and the pharmacological bases of antiepileptic treatment‏ ‎‡9 1‏
919 ‎‡a surgeryfortemporallobeepilepsyiseradicatingseizuresenough‏ ‎‡A [Surgery for temporal-lobe epilepsy: is eradicating seizures enough?]‏ ‎‡9 1‏
919 ‎‡a suddenaphasiainayoungwoman‏ ‎‡A [Sudden aphasia in a young woman]‏ ‎‡9 1‏
919 ‎‡a stiffpersonsyndromespsabasalgangliadiseasestriatalmrilesionsinapatientwithsps‏ ‎‡A Stiff person syndrome (SPS), a basal ganglia disease? Striatal MRI lesions in a patient with SPS.‏ ‎‡9 1‏
919 ‎‡a roleofhighdoselevetiracetamasaddontherapyforintractableepilepsycasereportandbriefreviewoftheliterature‏ ‎‡A Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature‏ ‎‡9 1‏
919 ‎‡a ringchromosome20epilepsysyndromeinchildrenelectroclinicalfeatures‏ ‎‡A Ring chromosome 20 epilepsy syndrome in children: electroclinical features‏ ‎‡9 1‏
919 ‎‡a retrospectivestudyofperampanelefficacyandtolerabilityinmyoclonicseizures‏ ‎‡A Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.‏ ‎‡9 1‏
919 ‎‡a responsetoimmunotherapyinantiiglon5diseaseasystematicreview‏ ‎‡A Response to immunotherapy in anti-IgLON5 disease: A systematic review‏ ‎‡9 1‏
919 ‎‡a regardingmosaicismandseizureonsetinringchromosome20syndrome‏ ‎‡A Regarding: 'Mosaicism and seizure onset in ring chromosome 20 syndrome'‏ ‎‡9 1‏
919 ‎‡a refractoryepilepsyinadults‏ ‎‡A [Refractory epilepsy in adults]‏ ‎‡9 1‏
919 ‎‡a pseudomigrainewithpleocytosisandtheinvisibilityoftheoriginalreportsinspanish‏ ‎‡A [Pseudomigraine with pleocytosis and the 'invisibility' of the original reports in Spanish.]‏ ‎‡9 1‏
919 ‎‡a preoperativeevaluationbyfunctionalmagneticresonanceimaginginpatientswithdysembryoplasticneuroepithelialtumoursacaseseries‏ ‎‡A Preoperative evaluation by functional magnetic resonance imaging in patients with dysembryoplastic neuroepithelial tumours: A case series‏ ‎‡9 1‏
919 ‎‡a possiblecaseofperipheralosmoticdemyelinationsyndrome‏ ‎‡A Possible case of peripheral osmotic demyelination syndrome‏ ‎‡9 1‏
919 ‎‡a partialepilepsyrefractorytomedicaltreatmentandoccipitalporencephaliclesion‏ ‎‡A [Partial epilepsy refractory to medical treatment and occipital porencephalic lesion]‏ ‎‡9 1‏
919 ‎‡a observationalmulticentrestudyintotheuseofantiepilepticdrugsinspanishneurologyconsultations‏ ‎‡A Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations.‏ ‎‡9 1‏
919 ‎‡a myastheniagravisinducedbyinmunocheckpointsinhibitors1casereportsecondarytoavelumabtherapyandreviewofpublishedcases‏ ‎‡A [Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases]‏ ‎‡9 1‏
919 ‎‡a multiplecerebralhaemorrhagesandantiplateletdrugs‏ ‎‡A Multiple cerebral haemorrhages and antiplatelet drugs‏ ‎‡9 1‏
919 ‎‡a millerfishersyndromeaftersarscov2infection‏ ‎‡A Miller-Fisher syndrome after SARS-CoV-2 infection‏ ‎‡9 1‏
919 ‎‡a migrainewithepisodicunilateralmydriasisparasympatheticdysfunctionoradrenergichyperactivity‏ ‎‡A [Migraine with episodic unilateral mydriasis: parasympathetic dysfunction or adrenergic hyperactivity?]‏ ‎‡9 1‏
919 ‎‡a mesialtemporalsclerosis1histologicaldataphysiopathologicalhypothesisandetiologicalfactors‏ ‎‡A Mesial temporal sclerosis (I): histological data, physiopathological hypothesis and etiological factors‏ ‎‡9 1‏
919 ‎‡a menstrualtensiontypeheadacheevidenceforitsexistence‏ ‎‡A Menstrual tension-type headache: evidence for its existence.‏ ‎‡9 1‏
919 ‎‡a malignantmiddlecerebralarteryinfarctionmedicalorsurgicaltreatment‏ ‎‡A [Malignant middle cerebral artery infarction: medical or surgical treatment?]‏ ‎‡9 1‏
919 ‎‡a lipidspecificimmunoglobulin1000bandsincerebrospinalfluidareassociatedwithareducedriskofdevelopingprogressivemultifocalleukoencephalopathyduringtreatmentwithnatalizumab‏ ‎‡A Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab‏ ‎‡9 1‏
919 ‎‡a ischemicstrokefollowingcisplatinand5fluorouraciltherapyatranscranialdopplerstudy‏ ‎‡A Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study‏ ‎‡9 1‏
919 ‎‡a incidenceandcasefatalityrateofcovid19inpatientswithactiveepilepsy‏ ‎‡A Incidence and case fatality rate of COVID-19 in patients with active epilepsy‏ ‎‡9 1‏
919 ‎‡a impactofsarscov2infectiononneurodegenerativeandneuropsychiatricdiseasesadelayedpandemic‏ ‎‡A Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic?‏ ‎‡9 1‏
919 ‎‡a hemifacialspasmasmanifestationofbenignintracranialhypertensionletter‏ ‎‡A [Hemifacial spasm as manifestation of benign intracranial hypertension. Letter]‏ ‎‡9 1‏
919 ‎‡a globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthe1yearofifnbetatreatment‏ ‎‡A Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment‏ ‎‡9 1‏
919 ‎‡a eslicarbazepineacetateinclinicalpracticeefficacyandsafetyresults‏ ‎‡A Eslicarbazepine acetate in clinical practice. Efficacy and safety results‏ ‎‡9 1‏
919 ‎‡a eslicarbazepineacetateandcarotidintimamediathicknessinepilepticpatients‏ ‎‡A Eslicarbazepine acetate and carotid intima-media thickness in epileptic patients.‏ ‎‡9 1‏
919 ‎‡a epidemiologyofepilepsyinspainandlatinamerica‏ ‎‡A [Epidemiology of epilepsy in Spain and Latin America]‏ ‎‡9 1‏
919 ‎‡a epidemiologicalfeaturesofepilepsyinadultsrequiringhospitaladmission‏ ‎‡A [Epidemiological features of epilepsy in adults requiring hospital admission]‏ ‎‡9 1‏
919 ‎‡a epiconconsensusrecommendationsforpropermanagementofswitchingtoeslicarbazepineacetateinepilepsy‏ ‎‡A EPICON consensus: recommendations for proper management of switching to eslicarbazepine acetate in epilepsy.‏ ‎‡9 1‏
919 ‎‡a efficacyofantiepilepticdrugsinautoimmuneepilepsyasystematicreview‏ ‎‡A Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review‏ ‎‡9 1‏
919 ‎‡a earlyaddonlacosamideinareallifesettingresultsofthereallystudy‏ ‎‡A Early add-on lacosamide in a real-life setting: results of the REALLY study‏ ‎‡9 1‏
919 ‎‡a designandvalidationofaquestionnaireformonitoringneurologicaldysphagiaandrespiratorydeteriorationinpatientswithamyotrophiclateralsclerosisderedela‏ ‎‡A Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)‏ ‎‡9 1‏
919 ‎‡a descriptiveanalysisoftheemaillistneurologiaredirishttplistservredirisesneurologiahtmlanactivepluralinstrumenthavingscientificqualityatthereachofthespanishspeakingneurologysector‏ ‎‡A [Descriptive analysis of the e-mail list "Neurología-RedIRIS" (http://listserv.rediris.es/neurologia.html): an active, plural instrument having scientific quality at the reach of the Spanish speaking neurology sector]‏ ‎‡9 1‏
919 ‎‡a crossreactivityofantibodiesagainstinterferonbetainmultiplesclerosispatientsandinterferenceofthejakstatsignalingpathway‏ ‎‡A Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway‏ ‎‡9 1‏
919 ‎‡a controversiesaboutthenewantiepilepticdrugs‏ ‎‡A Controversies about the new anti-epileptic drugs‏ ‎‡9 1‏
919 ‎‡a controlofseizuresindifferentstagesofpartialepilepsylacoexpaspanishretrospectivestudyoflacosamide‏ ‎‡A Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide.‏ ‎‡9 1‏
919 ‎‡a consensusclinicalpracticeguidelinesofthesociedadandaluzadeepilepsiaforthediagnosisandtreatmentofpatientswiththeir1epilepticseizureinemergencies‏ ‎‡A Consensus clinical practice guidelines of the Sociedad Andaluza de Epilepsia for the diagnosis and treatment of patients with their first epileptic seizure in emergencies‏ ‎‡9 1‏
919 ‎‡a consensusclinicalpracticeguidelinesoftheandalusianepilepsysocietytherapeuticrecommendationswhendealingwitha1epilepticseizureandinepilepticstatus‏ ‎‡A Consensus clinical practice guidelines of the Andalusian Epilepsy Society: therapeutic recommendations when dealing with a first epileptic seizure and in epileptic status‏ ‎‡9 1‏
919 ‎‡a cognitiveprofileofzonisamideandvalproicacidinthetreatmentofidiopathicgeneralizedepilepsyacomparativeobservationalstudy‏ ‎‡A Cognitive Profile of Zonisamide and Valproic Acid in the Treatment of Idiopathic Generalized Epilepsy: A Comparative Observational Study.‏ ‎‡9 1‏
919 ‎‡a characteristicsoftemporallobeepilepsywithnoictalimpairmentofconsciousness‏ ‎‡A Characteristics of temporal lobe epilepsy with no ictal impairment of consciousness.‏ ‎‡9 1‏
919 ‎‡a cerebralhemodynamicsinthesyndromeofpseudomigrainewithcsfpleocytosisatranscranialdopplerstudy‏ ‎‡A Cerebral hemodynamics in the syndrome of pseudomigraine with csf-pleocytosis:a transcranial doppler study‏ ‎‡9 1‏
919 ‎‡a antiepileptictreatmentinpatientswithepilepsyandothercomorbidities‏ ‎‡A Antiepileptic treatment in patients with epilepsy and other comorbidities.‏ ‎‡9 1‏
919 ‎‡a analysisoffactorsinfluencingtelephonecallresponserateinanepidemiologicalstudy‏ ‎‡A Analysis of factors influencing telephone call response rate in an epidemiological study.‏ ‎‡9 1‏
919 ‎‡a agraphiamanifestingduringawhatsappconversation‏ ‎‡A Agraphia manifesting during a WhatsApp conversation‏ ‎‡9 1‏
919 ‎‡a advancesinourknowledgeofthecausationandpathophysiologyofreflexepilepsies‏ ‎‡A [Advances in our knowledge of the causation and pathophysiology of reflex epilepsies]‏ ‎‡9 1‏
919 ‎‡a adultprevalenceofepilepsyinspainepiberiaapopulationbasedstudy‏ ‎‡A Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study.‏ ‎‡9 1‏
919 ‎‡a transcranialdopplerstudyininterictalmigraineandtensiontypeheadache‏ ‎‡A A transcranial doppler study in interictal migraine and tension-type headache.‏ ‎‡9 1‏
919 ‎‡a historicaldescriptionoftheassociationofmacroorchideamentalretardationandcranialdysmorphiainmalesfragile10chromosomesyndromebyabricherand‏ ‎‡A [A historical description of the association of macro-orchidea, mental retardation and cranial dysmorphia in males (fragile X chromosome syndrome) by A.B. Richerand].‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 PTBNP|1265201‏
996 ‎‡2 ISNI|0000000053203865‏
996 ‎‡2 DNB|1326184644‏
996 ‎‡2 PTBNP|1044696‏
996 ‎‡2 BNC|981058523370406706‏
996 ‎‡2 J9U|987007336081805171‏
996 ‎‡2 JPG|500037240‏
996 ‎‡2 LC|n 2018182679‏
996 ‎‡2 DNB|143093398‏
996 ‎‡2 DNB|1060667657‏
996 ‎‡2 LC|no2023013601‏
996 ‎‡2 J9U|987007285365605171‏
996 ‎‡2 BNCHL|10000000000000000070877‏
996 ‎‡2 ARBABN|000039881‏
996 ‎‡2 ARBABN|000039884‏
996 ‎‡2 CAOONL|ncf11018628‏
996 ‎‡2 BNE|XX1133402‏
996 ‎‡2 BNC|981058522373906706‏
996 ‎‡2 PTBNP|1642178‏
996 ‎‡2 SUDOC|035124016‏
996 ‎‡2 BNCHL|10000000000000000126736‏
996 ‎‡2 SUDOC|181359472‏
996 ‎‡2 ISNI|0000000498497050‏
996 ‎‡2 BNF|12390662‏
996 ‎‡2 SUDOC|121338363‏
996 ‎‡2 DNB|1115668889‏
996 ‎‡2 PTBNP|413636‏
996 ‎‡2 ISNI|0000000402959725‏
996 ‎‡2 LC|no 96038609‏
996 ‎‡2 LC|n 2005179185‏
996 ‎‡2 DNB|105661353X‏
996 ‎‡2 BLBNB|000280850‏
996 ‎‡2 RERO|A003083529‏
996 ‎‡2 ISNI|000000043691009X‏
996 ‎‡2 DNB|1266221352‏
996 ‎‡2 BNE|XX844725‏
996 ‎‡2 ISNI|0000000070422832‏
996 ‎‡2 ISNI|0000000070496196‏
996 ‎‡2 BNE|XX5438738‏
996 ‎‡2 BNE|XX5427654‏
996 ‎‡2 PTBNP|119843‏
996 ‎‡2 ISNI|0000000072828043‏
996 ‎‡2 BNC|981058614937806706‏
996 ‎‡2 ISNI|0000000066545872‏
996 ‎‡2 BNF|12217957‏
996 ‎‡2 BNE|XX1061246‏
996 ‎‡2 LC|n 90664211‏
996 ‎‡2 NUKAT|n 2006121129‏
996 ‎‡2 ARBABN|000048365‏
996 ‎‡2 BNF|12230372‏
996 ‎‡2 BIBSYS|4074663‏
996 ‎‡2 BNE|XX5506547‏
996 ‎‡2 BNE|XX1593615‏
996 ‎‡2 BNF|12537078‏
996 ‎‡2 ISNI|0000000116519921‏
996 ‎‡2 BNE|XX1064929‏
996 ‎‡2 DNB|1258321661‏
996 ‎‡2 BNF|16266894‏
996 ‎‡2 ARBABN|000036991‏
996 ‎‡2 ISNI|0000000078240128‏
996 ‎‡2 ISNI|0000000063012245‏
996 ‎‡2 BLBNB|000371468‏
996 ‎‡2 NKC|js20020115055‏
996 ‎‡2 BNE|XX1295956‏
996 ‎‡2 J9U|987007268761005171‏
996 ‎‡2 LC|no2001095530‏
996 ‎‡2 ISNI|0000000059628362‏
996 ‎‡2 DNB|105640275X‏
996 ‎‡2 LC|nr2004017608‏
996 ‎‡2 ISNI|0000000393774541‏
996 ‎‡2 LC|no2009008267‏
996 ‎‡2 ISNI|0000000060166169‏
996 ‎‡2 J9U|987007264463605171‏
996 ‎‡2 DNB|1209954087‏
996 ‎‡2 ISNI|0000000049554291‏
996 ‎‡2 DNB|120143801‏
996 ‎‡2 ISNI|0000000066323989‏
996 ‎‡2 DNB|1200499174‏
996 ‎‡2 BAV|495_360687‏
996 ‎‡2 BNE|XX1309072‏
996 ‎‡2 BNCHL|10000000000000000131510‏
996 ‎‡2 NKC|xx0317029‏
996 ‎‡2 ISNI|0000000374261214‏
996 ‎‡2 PTBNP|1436880‏
996 ‎‡2 J9U|987007259542205171‏
996 ‎‡2 BNE|XX947129‏
996 ‎‡2 DNB|143097830‏
996 ‎‡2 DNB|1057452165‏
996 ‎‡2 LC|nr2001007653‏
996 ‎‡2 ISNI|0000000060049894‏
996 ‎‡2 DNB|134222350‏
996 ‎‡2 BNE|XX1416926‏
996 ‎‡2 PTBNP|169519‏
996 ‎‡2 LC|no2015144522‏
996 ‎‡2 BNCHL|10000000000000000121218‏
996 ‎‡2 SUDOC|149864272‏
996 ‎‡2 BNF|12217455‏
996 ‎‡2 BLBNB|000154041‏
996 ‎‡2 ISNI|0000000025433014‏
996 ‎‡2 BLBNB|000154046‏
996 ‎‡2 ISNI|0000000070214048‏
996 ‎‡2 CAOONL|ncf11948847‏
996 ‎‡2 PTBNP|1685360‏
996 ‎‡2 ISNI|000000006979361X‏
996 ‎‡2 ISNI|0000000080071837‏
996 ‎‡2 ISNI|0000000064039423‏
996 ‎‡2 DNB|1340516217‏
996 ‎‡2 DNB|1210865874‏
996 ‎‡2 BNE|XX859998‏
996 ‎‡2 ISNI|0000000066464677‏
996 ‎‡2 BAV|495_56245‏
996 ‎‡2 DNB|1197307613‏
996 ‎‡2 BAV|495_56246‏
996 ‎‡2 BNC|981058511387006706‏
996 ‎‡2 DNB|1346993300‏
996 ‎‡2 BNC|981058508373406706‏
996 ‎‡2 SUDOC|124971547‏
996 ‎‡2 BNE|XX1184530‏
996 ‎‡2 LC|no 98013455‏
996 ‎‡2 BAV|495_368201‏
996 ‎‡2 ISNI|0000000068394959‏
996 ‎‡2 ISNI|0000000069391194‏
996 ‎‡2 DNB|1060083361‏
996 ‎‡2 ISNI|0000000110716297‏
996 ‎‡2 LC|no2001018873‏
996 ‎‡2 DNB|1055193286‏
996 ‎‡2 BNCHL|10000000000000000139211‏
996 ‎‡2 BNCHL|10000000000000000096924‏
996 ‎‡2 BNCHL|10000000000000000121143‏
996 ‎‡2 BNF|13535425‏
996 ‎‡2 ISNI|0000000391388284‏
996 ‎‡2 SUDOC|133464415‏
996 ‎‡2 PTBNP|1619868‏
996 ‎‡2 DNB|1160478694‏
996 ‎‡2 NUKAT|n 2008079307‏
996 ‎‡2 DNB|1056413808‏
996 ‎‡2 BNE|XX5446556‏
996 ‎‡2 DNB|1215286465‏
996 ‎‡2 RERO|A003083640‏
996 ‎‡2 BNE|XX6522475‏
996 ‎‡2 ISNI|0000000066381265‏
996 ‎‡2 ISNI|0000000068286130‏
996 ‎‡2 SZ|133923517‏
996 ‎‡2 DNB|1057423041‏
996 ‎‡2 PTBNP|43321‏
996 ‎‡2 BLBNB|000538906‏
996 ‎‡2 RERO|A027635219‏
996 ‎‡2 ISNI|0000000041140537‏
996 ‎‡2 ISNI|0000000019576772‏
996 ‎‡2 PTBNP|1554953‏
996 ‎‡2 PTBNP|1451613‏
996 ‎‡2 CAOONL|ncf10694072‏
996 ‎‡2 CAOONL|ncf10694074‏
996 ‎‡2 BNCHL|10000000000000000104445‏
996 ‎‡2 BIBSYS|10041369‏
996 ‎‡2 LC|no 92032433‏
996 ‎‡2 ISNI|0000000038099844‏
996 ‎‡2 SUDOC|169676218‏
996 ‎‡2 DNB|1103682008‏
996 ‎‡2 LC|no2023115632‏
996 ‎‡2 BNC|981058515555406706‏
996 ‎‡2 PLWABN|9810537494505606‏
996 ‎‡2 BNE|XX1763458‏
996 ‎‡2 DNB|1056374942‏
996 ‎‡2 BNC|981058521714206706‏
996 ‎‡2 DNB|1300294159‏
996 ‎‡2 BAV|495_231218‏
996 ‎‡2 SUDOC|063871580‏
996 ‎‡2 LC|no2006133886‏
996 ‎‡2 PTBNP|1671344‏
996 ‎‡2 JPG|500253950‏
996 ‎‡2 JPG|500411798‏
996 ‎‡2 DNB|132915278‏
996 ‎‡2 ISNI|000000004202866X‏
996 ‎‡2 BNCHL|10000000000000000120594‏
996 ‎‡2 NKC|mub2011626571‏
996 ‎‡2 JPG|500050559‏
996 ‎‡2 PTBNP|119078‏
996 ‎‡2 BNE|XX942603‏
996 ‎‡2 BNCHL|10000000000000000129596‏
996 ‎‡2 PTBNP|1755692‏
996 ‎‡2 SUDOC|116372427‏
996 ‎‡2 PTBNP|265877‏
996 ‎‡2 SUDOC|147757002‏
996 ‎‡2 ISNI|000000011439984X‏
996 ‎‡2 BNC|981058520829306706‏
996 ‎‡2 LC|nr2003039889‏
996 ‎‡2 SUDOC|194963837‏
996 ‎‡2 BAV|495_40213‏
996 ‎‡2 BAV|495_40212‏
996 ‎‡2 ISNI|0000000070124413‏
996 ‎‡2 PTBNP|1578554‏
996 ‎‡2 BNE|XX5476936‏
996 ‎‡2 RERO|A011899554‏
996 ‎‡2 NUKAT|n 98035305‏
996 ‎‡2 LC|n 86148608‏
996 ‎‡2 LC|n 00001482‏
996 ‎‡2 LC|ns2013001139‏
996 ‎‡2 PTBNP|216944‏
996 ‎‡2 ISNI|0000000032073125‏
996 ‎‡2 LC|nr2002005625‏
996 ‎‡2 BNE|XX939831‏
996 ‎‡2 BNE|XX1405660‏
996 ‎‡2 LC|no2017091872‏
996 ‎‡2 LC|n 86065631‏
996 ‎‡2 BNC|981058617434106706‏
996 ‎‡2 LC|n 78072330‏
996 ‎‡2 ISNI|0000000042340629‏
996 ‎‡2 RERO|A024769699‏
996 ‎‡2 ISNI|0000000045919388‏
996 ‎‡2 RERO|A003846529‏
996 ‎‡2 BNE|XX1165722‏
996 ‎‡2 DBC|87097969416918‏
996 ‎‡2 LC|n 81030506‏
996 ‎‡2 LC|nr 00033999‏
996 ‎‡2 BNE|XX1045887‏
996 ‎‡2 SUDOC|087611112‏
996 ‎‡2 DNB|128698002X‏
996 ‎‡2 ISNI|0000000049574372‏
996 ‎‡2 ISNI|0000000439837035‏
996 ‎‡2 PTBNP|1767417‏
996 ‎‡2 SUDOC|145737454‏
996 ‎‡2 ISNI|0000000385873232‏
996 ‎‡2 SUDOC|102215235‏
996 ‎‡2 DNB|1056629878‏
996 ‎‡2 NKC|js20020115083‏
996 ‎‡2 ISNI|0000000114809394‏
996 ‎‡2 CAOONL|ncf11347131‏
996 ‎‡2 BAV|495_256427‏
996 ‎‡2 NSK|000357846‏
996 ‎‡2 PTBNP|1750879‏
996 ‎‡2 PTBNP|285220‏
996 ‎‡2 LC|no 96032185‏
996 ‎‡2 BNC|981061108226206706‏
996 ‎‡2 DNB|1243909471‏
996 ‎‡2 ISNI|0000000123271004‏
996 ‎‡2 PTBNP|1377347‏
996 ‎‡2 LC|nr 92005138‏
996 ‎‡2 ISNI|0000000060874069‏
996 ‎‡2 PTBNP|1732492‏
996 ‎‡2 LC|n 2007034772‏
996 ‎‡2 BNE|XX1532555‏
996 ‎‡2 LC|no 00078643‏
996 ‎‡2 DNB|125804415‏
996 ‎‡2 LC|n 2010035984‏
996 ‎‡2 BNE|XX1165580‏
996 ‎‡2 ISNI|0000000382701195‏
996 ‎‡2 LC|n 2014055206‏
996 ‎‡2 SUDOC|178984647‏
996 ‎‡2 ISNI|0000000067621005‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏